Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

What’s more, the rise of technology in medicine, while beneficial in many ways, has further reduced the use of empathic touch ...

The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These ...

A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about ...

Former HHS Secretary Tom Price writes that the new Trump administration should update immigration laws to help the U.S.

MAHA supporters share a disturbing sense that the health care system and its regulators don’t have people’s best interests at heart ...

First-of-its-kind data analysis finds UnitedHealth Group pays many of its own physician practices significantly more than the ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...

Join clinical experts as they address treatment challenges for breast cancer patients & explore the latest advancements at ...